3E Bioventures Capital is a healthcare-focused venture capital firm founded in 2015, with a presence in both Beijing and Palo Alto. The investment team comprises professionals trained in biomedical fields, possessing extensive experience in the healthcare industry and a successful track record in investment and entrepreneurship within China. The firm invests in early and growing stage companies, targeting sectors such as healthcare devices, services, drug discovery, diagnostics, and healthcare IT. With funds managed in both RMB and US dollars, 3E Bioventures Capital aims to capitalize on the significant growth opportunities in China's healthcare market over the next decade or two. The firm is committed to leveraging its expertise to build successful healthcare ventures and generate returns for its investors, while also establishing itself as a notable international brand in healthcare investment.
CytoNiche focuses on the development of 3D micro-organization engineering technology. The core technology is derived from the transformation of Tsinghua University's achievements. Based on its original research technology, Huasheng Bio has launched a series of related products and services, including customized, large-scale, automated and intelligent stem cell culture. Amplification process; 3D stem cell micro-tissue regeneration treatment of new drugs and 3D cell high-throughput drug screening products.
Dermaliq Therapeutics focuses on developing advanced skincare therapies aimed at treating follicular diseases, including androgenetic alopecia and alopecia areata. The company utilizes its proprietary technology, hyliQ™, which enhances targeted drug delivery into skin tissues while minimizing unwanted side effects. This innovative approach allows for the creation of effective liquid drug products that not only provide therapeutic benefits but also possess excellent cosmetic properties. By leveraging this unique technology, Dermaliq strives to improve treatment outcomes for millions of patients in need of effective skincare solutions.
Zhengli Technology is a company dedicated to the research, development, production, and sales of advanced invisible orthodontic products, dental restoration items, and specialized dental software systems. It aims to provide comprehensive solutions for dental professionals both in China and internationally. The company’s primary focus is on creating invisible orthodontic appliances that assist patients in enhancing their dental health and straightening their teeth. Through its innovative products and services, Zhengli Technology strives to support dental practitioners in delivering effective care to their patients.
ITabMed is a clinical-stage biotech company located in Shanghai, China. The company was founded in 2020 and is registered in Lin Gang Sci-Tech City, Shanghai. It was a spin-off entity from the former “Generon BioMed Ltd.”. The company is focused on immunotherapy drug research and development to treat cancer.
Neural Galaxy is a brain science company that originated at Harvard Medical School and the Massachusetts Institute of Technology. The mission of Younao Galaxy is to help solve brain diseases and achieve greater intelligence. Focusing on global vision, based on breakthrough brain science research results, using new software and hardware technologies, Younao Galaxy helps humans to deeply understand our brains, understand high-level intelligence, and solve the enormous challenges facing human society.
Alebund Pharmaceuticals
Series B in 2021
Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.
Cullgen Inc. is a biopharmaceutical company based in San Diego, California, established in 2018. The company focuses on developing innovative new chemical entities (NCEs) aimed at treating diseases that currently lack effective therapeutic options. Utilizing its proprietary uSMITE™ platform, Cullgen employs targeted protein degradation technology to selectively degrade disease-causing proteins. This approach is particularly significant for addressing cancer, inflammatory, and autoimmune diseases, including targets that have been deemed undruggable. By providing novel therapeutic strategies, Cullgen aims to enhance drug discovery and offer new avenues for treating debilitating conditions.
Cardea Bio, Inc. is a biotechnology company based in San Diego, California, specializing in bioelectronics and graphene-based digital biosensor technology. Founded in 2013, the company develops products that facilitate precision healthcare by enhancing the ease, speed, and cost-effectiveness of diagnostics. Its key offerings include AGILE R100, an innovative assay for small molecule drug discovery, and AGILE R200, an automated high-throughput screening solution. Cardea's biosensors utilize biocompatible graphene to transform biological signals into digital data, enabling real-time analysis of biomolecules. This technology supports applications in small molecule validation, antibody characterization, and biomolecular analysis, serving the life sciences and healthcare sectors. The company also sells its products online, contributing to advancements in research and diagnostics.
Bayland Scientific
Seed Round in 2021
Bayland Scientific specializes in the fields of biotechnology and life science.
Neural Galaxy is a brain science company that originated at Harvard Medical School and the Massachusetts Institute of Technology. The mission of Younao Galaxy is to help solve brain diseases and achieve greater intelligence. Focusing on global vision, based on breakthrough brain science research results, using new software and hardware technologies, Younao Galaxy helps humans to deeply understand our brains, understand high-level intelligence, and solve the enormous challenges facing human society.
Shanton Pharma Co., Ltd. is a biotechnology research organization founded in 2016 and based in Shanghai, China. The company specializes in the research and development of drugs aimed at addressing significant unmet medical needs. Shanton Pharma focuses on therapeutic areas related to uric acid metabolism, inflammatory pain, and gout metabolic syndrome, employing advanced and innovative ideas in drug research. Its commitment to pharmaceutical research positions it as a key player in the biotechnology sector, striving to develop effective therapies for pressing health challenges.
Subtle Medical, Inc., a healthcare technology company, develops medical imaging software for clinical imaging centers and hospitals. Its product includes SubtleMR, an artificial intelligence-based image processing software that reduces image noise and increases image sharpness for non-contrast enhanced magnetic resonance imaging (MRI). It enables to reduce cost, imaging time, and radiation/contrast dose. The company was founded in 2017 and is based in Menlo Park, California.
Biocytogen is a biotechnology company that specializes in developing gene-targeted animal models for life science research. Founded in 2008, with headquarters in Beijing, China, and additional facilities in the United States, Biocytogen offers a range of services including customized and off-the-shelf mouse models, as well as phenotype analysis across various biological areas such as immunology, neurology, and cancer. The company utilizes advanced gene-targeting platforms to create a variety of genetically modified animals, including humanized models and knockouts, to support preclinical studies. Biocytogen also provides pharmacology services related to tumor immunity and autoimmunity, and it markets its products online. With a commitment to integrating resources from both China and the United States, Biocytogen aims to be a leading global supplier of gene-targeted animal models.
OncoImmune is a clinical-stage biopharmaceutical company that engages in the discovery and development of biopharmaceuticals for the treatment of cancer and autoimmune disease. It has completed a Phase II clinical trial of CD24Fc for the prophylactic treatment of acute Graft versus Host Disease for leukemia patients undergoing hematopoietic stem cell transplantation and is poised to launch a pivotal trial for the indication.
Oncolmmune was founded in 2000 and is based in Rockville, Maryland.
Regenacy Pharmaceuticals, LLC is a biopharmaceutical company based in Boston, Massachusetts, established in 2016. The company focuses on developing innovative treatments for peripheral neuropathies, hemoglobinopathies, and specific oncology indications. Its primary compound, ricolinostat, is an oral, selective inhibitor of the enzyme HDAC6, aimed at restoring normal nerve function rather than merely managing pain and symptoms. Currently positioned to enter Phase 2 clinical trials, ricolinostat shows promise for treating various forms of peripheral neuropathy, including diabetic, chemotherapy-induced, and inherited types, supported by preclinical studies that demonstrate its ability to regenerate normal protein function. Additionally, the company is exploring the potential applications of ricolinostat in treating sickle cell disease and beta-thalassemia.
Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for the treatment of cancer. The company develops a pipeline of therapies and product candidates, including APX005M and APX201 for immuno-oncology, APX003/BD0801 and TRK-950 for oncology, APX001/SSS07 for inflammation, and APX003/TK001 for ocular diseases. It also develops APXiMAB platform, which enables discovery of antibodies for novel immune system targets. The company was founded in 2010 and is based in San Carlos, California.
Lipidio Pharmaceuticals Inc., a biopharmaceuticals company, develops and manufactures drugs to treat diseases associated with excess body fat. It offers GDD3898, a treatment candidate for Prader Willi syndrome (PWS), nonalcoholic steatohepatitis (NASH), and other conditions associated with obesity. Lipidio Pharmaceuticals Inc. was formerly known as GDD Therapeutics, Inc and changed its name to Lipidio Pharmaceuticals Inc. in May, 2019. The company was incorporated in 2018 and is based in San Diego, California.
Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of unique host-directed anti-viral. The company is committed to developing safe and effective immuno-biologic therapies to treat the most vulnerable patients. Its founders were ingenious virologists and molecular biologists who realized that targeting a virus is difficult due to the virus’s ability to mutate and avoid the treatment. This ability to mutate also enables the virus to evade vaccines. So instead of trying to hit a moving target, they developed an innovative new approach to fight respiratory viruses: they targeted the host instead of the virus.
The company was founded in 2003 and is headquartered in San Diego, California.
Biocytogen is a biotechnology company that specializes in developing gene-targeted animal models for life science research. Founded in 2008, with headquarters in Beijing, China, and additional facilities in the United States, Biocytogen offers a range of services including customized and off-the-shelf mouse models, as well as phenotype analysis across various biological areas such as immunology, neurology, and cancer. The company utilizes advanced gene-targeting platforms to create a variety of genetically modified animals, including humanized models and knockouts, to support preclinical studies. Biocytogen also provides pharmacology services related to tumor immunity and autoimmunity, and it markets its products online. With a commitment to integrating resources from both China and the United States, Biocytogen aims to be a leading global supplier of gene-targeted animal models.
Provider of a medical platform designed to provide users with psychological and mental health support services. The company's services include health consultation, doctor-patient communication services, one-on-one appointment consultation and pre-diagnosis, enabling patients and doctors to communicate easily online while having their information protected.
Medtrum Technologies Inc. specializes in the development and delivery of medical devices for diabetes management. The company offers a range of products, including the A6 TouchCare System, a tubing-free semi-closed loop insulin management system that integrates an insulin patch pump and continuous glucose monitoring system (CGMS) with predictive low glucose suspend capabilities. Additionally, it provides the S6 EasySense disposable CGM system, which features a waterproof design and a hair-like sensor for real-time glucose monitoring over a week, and the P6 EasyPatch disposable pump that allows for adjustable basal rates and on-demand bolus delivery. Medtrum also incorporates a cloud-based healthcare system, featuring the EasyTouch mobile application and EasyView web portal, which enhances diabetes management by providing comprehensive data for patients, families, and healthcare providers. Founded in 2008 and headquartered in Shanghai, China, Medtrum operates in multiple locations, including Düsseldorf, Germany; Hong Kong; and Watford, United Kingdom.
Cytek Biosciences, Inc. specializes in manufacturing and selling innovative flow cytometry tools and equipment for cancer and cell biology research. The company offers advanced instruments such as the Cytek Aurora and Cytek Northern Lights, which are full-spectrum flow cytometers designed for high-resolution and high-sensitivity cell analysis. Additionally, Cytek provides the DxP Athena system, which utilizes its proprietary technology to resolve dim populations in multicolor formats, along with the QbSure quality control program to ensure optimal performance of cytometers. The company also develops proprietary cFluor reagents that enhance the performance of its instruments in complex multicolor environments. Headquartered in Fremont, California, Cytek has expanded its global presence with locations in Maryland, the Netherlands, Japan, and China, aiming to make flow cytometry more accessible for researchers and clinicians worldwide.
Profusa, Inc. is a digital health technology company based in Emeryville, California, specializing in the development of tissue-integrated sensors and biosensors aimed at enhancing diabetes management and chronic disease care. Founded in 2009, Profusa focuses on creating biointegrated sensors that allow individuals to monitor their unique body chemistry in real time, thereby transforming personal health management. The company's technology is designed to be user-friendly and cost-effective, providing actionable, clinical-grade data to improve health outcomes. Profusa also develops software that offers biofeedback for chronic disease management and promotes healthy living. Its flagship product, Lumee Oxygen, represents a significant advancement in continuous health monitoring within the European market.
Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for the treatment of cancer. The company develops a pipeline of therapies and product candidates, including APX005M and APX201 for immuno-oncology, APX003/BD0801 and TRK-950 for oncology, APX001/SSS07 for inflammation, and APX003/TK001 for ocular diseases. It also develops APXiMAB platform, which enables discovery of antibodies for novel immune system targets. The company was founded in 2010 and is based in San Carlos, California.
Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of unique host-directed anti-viral. The company is committed to developing safe and effective immuno-biologic therapies to treat the most vulnerable patients. Its founders were ingenious virologists and molecular biologists who realized that targeting a virus is difficult due to the virus’s ability to mutate and avoid the treatment. This ability to mutate also enables the virus to evade vaccines. So instead of trying to hit a moving target, they developed an innovative new approach to fight respiratory viruses: they targeted the host instead of the virus.
The company was founded in 2003 and is headquartered in San Diego, California.
Refuge Biotechnologies, Inc. is a Menlo Park, California-based company focused on developing cancer immunotherapies. Established in 2015, it utilizes synthetic biology and gene-editing technology, specifically CRISPR-dCas, to create innovative treatments. The company's approach involves engineering cell therapies that can sense their environment and simultaneously activate or repress multiple genes. This strategy aims to enhance the effectiveness and precision of cancer treatments, moving beyond traditional methods that target a single function. Through its research and development efforts, Refuge Biotechnologies is dedicated to advancing cancer diagnostics and therapies to improve patient outcomes.
Biocytogen is a biotechnology company that specializes in developing gene-targeted animal models for life science research. Founded in 2008, with headquarters in Beijing, China, and additional facilities in the United States, Biocytogen offers a range of services including customized and off-the-shelf mouse models, as well as phenotype analysis across various biological areas such as immunology, neurology, and cancer. The company utilizes advanced gene-targeting platforms to create a variety of genetically modified animals, including humanized models and knockouts, to support preclinical studies. Biocytogen also provides pharmacology services related to tumor immunity and autoimmunity, and it markets its products online. With a commitment to integrating resources from both China and the United States, Biocytogen aims to be a leading global supplier of gene-targeted animal models.
Eucure (Beijing) Biopharma Co., Ltd is a biotechnology company based in Beijing, China, specializing in the discovery and development of immuno-oncology targeted antibodies, particularly focusing on immune checkpoints. Founded in 2016, Eucure offers services including antibody production, in vivo drug efficacy testing, and in vitro efficacy evaluations. The company has a robust pipeline featuring multiple drug candidates, including YH-001 through YH-008. Several of these products have progressed to the CMC stage and have applied for clinical trials as of 2019. Eucure's mission is to create innovative antibody treatments aimed at improving survival rates for patients with tumors, reflecting its commitment to advancing cancer therapy. As of August 2020, Eucure operates as a subsidiary of Beijing Biocytogen Co., Ltd.
Ligatech Bioscience is an intrusive consumables developer specializing in the development and manufacture of medical devices for the field of sports medicine, as well as the development and production of biomedical materials and products. A production line for artificial ligaments and artificial ligament fixation systems has been established. And provide users with relevant technical advice and technical services.
EpimAb Biotherapeutics is a biopharmaceutical company based in Shanghai, China, focused on the research and development of novel bispecific antibody therapeutics. Utilizing its proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform, the company creates bispecific molecules that possess antibody-like properties. This innovative approach aims to address the challenges associated with developing effective bi-specific antibodies, which are engineered from two different monoclonal antibodies to combine their therapeutic features into a single entity. These bispecific antibodies hold promise for treating various life-threatening conditions, particularly in immuno-oncology, by offering new therapeutic options. Despite the potential benefits of bi-specific antibodies, many candidates face hurdles in development due to issues related to their binding properties, pharmacokinetics, and production costs. EpimAb Biotherapeutics is positioned to contribute to the growing need for advanced bi-specific therapeutics in the pharmaceutical industry.
OncoImmune is a clinical-stage biopharmaceutical company that engages in the discovery and development of biopharmaceuticals for the treatment of cancer and autoimmune disease. It has completed a Phase II clinical trial of CD24Fc for the prophylactic treatment of acute Graft versus Host Disease for leukemia patients undergoing hematopoietic stem cell transplantation and is poised to launch a pivotal trial for the indication.
Oncolmmune was founded in 2000 and is based in Rockville, Maryland.
MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient infrastructure and scientific resources available in China. This hybrid business model enables MicuRx to implement an accelerated global development strategy with a goal of completing Phase II trials for its drug candidates in both the United States and China.
Refuge Biotechnologies, Inc. is a Menlo Park, California-based company focused on developing cancer immunotherapies. Established in 2015, it utilizes synthetic biology and gene-editing technology, specifically CRISPR-dCas, to create innovative treatments. The company's approach involves engineering cell therapies that can sense their environment and simultaneously activate or repress multiple genes. This strategy aims to enhance the effectiveness and precision of cancer treatments, moving beyond traditional methods that target a single function. Through its research and development efforts, Refuge Biotechnologies is dedicated to advancing cancer diagnostics and therapies to improve patient outcomes.
Profusa, Inc. is a digital health technology company based in Emeryville, California, specializing in the development of tissue-integrated sensors and biosensors aimed at enhancing diabetes management and chronic disease care. Founded in 2009, Profusa focuses on creating biointegrated sensors that allow individuals to monitor their unique body chemistry in real time, thereby transforming personal health management. The company's technology is designed to be user-friendly and cost-effective, providing actionable, clinical-grade data to improve health outcomes. Profusa also develops software that offers biofeedback for chronic disease management and promotes healthy living. Its flagship product, Lumee Oxygen, represents a significant advancement in continuous health monitoring within the European market.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.